Healthcare Services Group, Inc. (HCSG)
NASDAQ: HCSG · Real-Time Price · USD
14.00
+0.02 (0.18%)
At close: Aug 6, 2025, 4:00 PM
13.99
0.00 (-0.04%)
After-hours: Aug 6, 2025, 4:20 PM EDT
Revance Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts that cover Revance Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $16.25, which forecasts a 16.11% increase in the stock price over the next year. The lowest target is $15 and the highest is $19.
Price Target: $16.25 (+16.11%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Revance Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 3 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Macquarie | Macquarie | Hold → Buy Upgrades $15 → $16 | Hold → Buy | Upgrades | $15 → $16 | +14.33% | Jul 29, 2025 |
| Benchmark | Benchmark | Strong Buy Maintains $17 → $19 | Strong Buy | Maintains | $17 → $19 | +35.76% | Jul 24, 2025 |
| Baird | Baird | Hold Maintains $13 → $15 | Hold | Maintains | $13 → $15 | +7.18% | Jul 24, 2025 |
| Macquarie | Macquarie | Hold Maintains $15 | Hold | Maintains | $15 | +7.18% | Apr 28, 2025 |
| Baird | Baird | Hold Maintains $12 → $13 | Hold | Maintains | $12 → $13 | -7.11% | Apr 24, 2025 |
Financial Forecast
Revenue This Year
1.86B
from 1.72B
Increased by 8.35%
Revenue Next Year
1.95B
from 1.86B
Increased by 5.00%
EPS This Year
0.86
from 0.53
Increased by 61.78%
EPS Next Year
0.92
from 0.86
Increased by 7.19%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 1.9B | 2.0B | 2.1B |
| Avg | 1.9B | 2.0B | 2.1B |
| Low | 1.8B | 1.8B | 2.0B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 12.1% | 9.7% | 9.6% |
| Avg | 8.4% | 5.0% | 5.7% |
| Low | 3.0% | -0.8% | 0.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.91 | 1.02 | 1.12 |
| Avg | 0.86 | 0.92 | 1.06 |
| Low | 0.78 | 0.78 | 0.99 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 72.4% | 18.8% | 22.2% |
| Avg | 61.8% | 7.2% | 15.3% |
| Low | 47.9% | -8.6% | 7.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.